ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CAT Catco Reinsurance Opportunities Fund Limited

25.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Catco Reinsurance Opportunities Fund Limited LSE:CAT London Ordinary Share BMG1961Q3242 ORD USD0.00013716 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 25.00 14.00 36.00 25.00 25.00 25.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Unit Inv Tr, Closed-end Mgmt 6.33M 5.44M 3.6440 6.86 37.33M

Director Shareholding

19/05/2005 1:31pm

UK Regulatory


RNS Number:5215M
Cambridge Antibody Tech Group PLC
19 May 2005

                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology



2)  Name of director
John Stocker


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Greenwood Nominees Limited


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)


7)  Number of shares/amount of
    stock acquired
274


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005


14) Date company informed
19 May 2005


15) Total holding following this notification
82,460


16) Total percentage holding of issued class following this notification
0.160


If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.


24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005









                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology



2)  Name of director

Ake Stavling


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Greenwood Nominees Limited


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)

7)  Number of shares/amount of
    stock acquired
274


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005


14) Date company informed
19 May 2005


15) Total holding following this notification
2,616


16) Total percentage holding of issued class following this notification
0.005%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.


24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005







                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology



2)  Name of director
Sir Aaron Klug


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Greenwood Nominees Limited


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)


7)  Number of shares/amount of
    stock acquired
274


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005


14) Date company informed
19 May 2005


15) Total holding following this notification
28,201


16) Total percentage holding of issued class following this notification
0.055%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.



24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005









                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
Peter Ringrose


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Greenwood Nominees Limited


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)


7)  Number of shares/amount of
    stock acquired
274


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005


14) Date company informed
19 May 2005


15) Total holding following this notification
3,436


16) Total percentage holding of issued class following this notification
0.007%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.



24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005





                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
Professor Christopher Marshall


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Greenwood Nominees Limited


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)


7)  Number of shares/amount of
    stock acquired
274


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005

14) Date company informed
19 May 2005


15) Total holding following this notification
501


16) Total percentage holding of issued class following this notification
0.001%





If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.


24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005





                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
Dr Paul Nicholson


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Dr Paul Nicholson


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)

7)  Number of shares/amount of
    stock acquired
659


8)  Percentage of issued class
0.0013%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005


14) Date company informed
19 May 2005


15) Total holding following this notification
10,269


16) Total percentage holding of issued class following this notification
0.019%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.



24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005




                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS


1)  Name of company
Cambridge Antibody Technology


2)  Name of director
Professor Uwe Bicker


3)  Please state whether notification indicates that it is in respect of
    holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above


4)  Name of the registered holder(s) and, if more than one holder, the
    number of shares held by each of them (if notified)
Professor Uwe Bicker


5)  Please state whether notification relates to a person(s) connected
    with the Director named in 2 above and identify the connected person(s)
As in 2 above


6)  Please state the nature of the transaction. For PEP transactions
    please indicate whether general/single co PEP and if discretionary/non
    discretionary
Quarterly payment of part of directors fees in lieu of cash consideration (see
notes at 23)


7)  Number of shares/amount of
    stock acquired
274


8)  Percentage of issued class
0.0005%


9)  Number of shares/amount
    of stock disposed
Nil


10) Percentage of issued class
Nil


11) Class of security
Ordinary 10 pence shares


12) Price per share
#5.69


13) Date of transaction
19 May 2005


14) Date company informed
19 May 2005


15) Total holding following this notification
6,319


16) Total percentage holding of issued class following this notification
0.012%


If a director has been granted options by the company please complete the
following boxes

17) Date of grant



18) Period during which or date on which exercisable



19) Total amount paid (if any) for grant of the option



20) Description of shares or debentures involved: class, number



21) Exercise price (if fixed at time of grant) or indication that price
    is to be fixed at time of exercise



22) Total number of shares or debentures over which options held
    following this notification



23) Any additional information
The practice of issuing shares in lieu of part of the basic directors fee has
been established by the Company for some time. In November 2004 the Board
resolved that such issue of shares would occur on a quarterly rather than an
annual basis.  The share price used is the average closing price of one CAT
share for the three trading days preceding 19 May 2005.



24) Name of contact and telephone number for queries
Justin Hoskins, 01223 898589


25) Name and signature of authorised company official responsible for
    making this notification

    Date of Notification..19 May 2005




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSEAASNFANSEFE

1 Year Catco Reinsurance Opport... Chart

1 Year Catco Reinsurance Opport... Chart

1 Month Catco Reinsurance Opport... Chart

1 Month Catco Reinsurance Opport... Chart

Your Recent History

Delayed Upgrade Clock